Physician profile
Anton Kapp
NPI 1861457145
$3,146.23
in general payments reported to CMS, 2019-2025
35 companies · $410 in 2025
The $410 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $381 · 2021: $212 · 2022: $366 · 2023: $618 · 2024: $568 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,595.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $612.09 | 2019-2025 | Xtandi, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $271.86 | 2019-2025 | |
| Janssen Biotech, INC. | $262.43 | 2020-2025 | Erleada |
| Ferring Pharmaceuticals INC. | $261.49 | 2019-2025 | Adstiladrin |
| Dendreon Pharmaceuticals LLC | $224.98 | 2019-2023 | Provenge |
| Pfizer INC. | $210.84 | 2022-2025 | |
| Medtronic, INC. | $146.28 | 2022-2024 | Interstim |
| Boston Scientific Corporation | $86.07 | 2019-2023 | Rezum Generator |
| Progenics Pharmaceuticals, INC. | $84.72 | 2022-2024 | |
| Mission Pharmacal Company | $79.21 | 2019-2023 | Uribel |
| Sumitomo Pharma America, INC. | $74.51 | 2023-2025 | Orgovyx, Gemtesa |
| Urogen Pharma, INC. | $67.96 | 2024-2025 | |
| Endo USA, INC. | $59.64 | 2024-2025 | Xiaflex |
| Sun Pharmaceutical Industries INC. | $58.12 | 2019-2020 | |
| Abbvie INC. | $58.03 | 2024-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $52.86 | 2019-2025 | Xyosted |
| Novartis Pharmaceuticals Corporation | $45.23 | 2024-2025 | |
| Myovant Sciences INC. | $44.46 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $42.24 | 2022 | |
| Dentsply Ih INC. | $40.58 | 2019-2021 | |
| Convatec INC. | $37.76 | 2022 | |
| Conmed Corporation | $35.05 | 2022 | |
| Tolmar, INC. | $34.30 | 2024-2025 | Eligard, Jatenzo |
| Endo Pharmaceuticals INC. | $32.98 | 2023 | Xiaflex |
| Teleflex LLC | $27.79 | 2022-2025 | Barrigel |
| Azurity Pharmaceuticals, INC. | $24.99 | 2025 | Azmiro |
| Amgen INC. | $23.87 | 2020 | |
| Telix Pharmaceuticals | $23.40 | 2023 | Illuccix |
| Allergan, INC. | $22.90 | 2021 | |
| Neotract INC. | $20.32 | 2019 | |
| Braintree Laboratories, INC. | $18.67 | 2023 | Sutab |
| Coloplast Corp | $16.76 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $15.04 | 2022 | |
| 180 Medical, INC. | $14.99 | 2020 | |
| Immunitybio, INC. | $13.81 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anton Kapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.